Docket No.:

GNE.3230R1C61

Please Direct All Correspondence to Customer Number 30.313

TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

Goddard, et al.

App. No

10/063,587

May 3, 2002

Filed

SECRETED AND TRANSMEMBRANE

For

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Examiner

Claire M. Kaufman

Art Unit

1646

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing 42 references.
 - (X) Enclosing 29 references.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

1781257/jk 062105

Docket No.: GNE.3230R1C61

INFORMATION DISCLOSURE STATEMENT

pplicant

Goddard, et al.

App. No

10/063,587

Filed

N/a-- 2 2002

- ----

May 3, 2002

For

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Examiner

Claire M. Kaufman

Art Unit

1646

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 42 references to be considered by the Examiner. Also enclosed are 29 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

By:

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

1781679/jk 062105

_			F 10/3B/08 Equivalent
6	IPE	Application No.	10/063,587
/	SNATORMATION DISCLOSURE	Filing Date	May 3, 2002
JUL	1 1 2005 TATEMENT BY APPLICANT	First Named Inventor	Goddard, et al.
•	WOUNT	Art Unit	1646
REELS.	(Multiple sheets used when necessary)	Examiner	Claire M. Kaufman
	SHEET 1 OF 3	Attorney Docket No.	GNE.3230R1C61

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	1	6,025,156	02-15-2000	Gwynn, et al.		
	2	6,124,433	09-26-2000	Falb, et al.		
	3	6,156,500	12-05-2000	Falb, Dean		
	4	6,162,604	12-19-2000	Jacob, Chaim O.		
	5	6,228,582	05-08-2001	Rodier, et al.		
	6	6,395,306	05-28-2002	Cui, et al.		
	7	6,414,117	07-02-2002	Levinson, D. A.		
	8	6,465,185	10-15-2002	Goldfine, et al.		
	9	6,498,235	12-24-2002	Sheppard, et al.		
	10	6,562,343	05-13-2003	Levinson, D. A.		
	11	6,645,499	11-11-2003	Lal, et al.		
	12	6,730,502	05-04-2004	Van Hijum, et al.		
	13	6,737,522	05-18-2004	Sundick, et al.		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹			
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.				
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.				
	16	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.				
	17	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular & Cellular Proteomics 1.4, 304-313.				
	18	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal, Vol. 15, No. 16,</i> pp. 4392-4401.				
	19	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C βII is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research, Vol. 61</i> , pp.1375-1381.				
	20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.				

Examiner Signature	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

Application No. 10/063,587 INFORMATION DISCLOSURE Filing Date May 3, 2002 First Named Inventor Goddard, et al. ATEMENT BY APPLICANT Art Unit 1646 JUL 1 2005 Multiple sheets used when necessary) Examiner Claire M. Kaufman SHEET 2 OF 3 Attorney Docket No. GNE.3230R1C61

<u> </u>	giviuiui	pie sneets used when necessary)	Examiner	Ciaire IVI. Nauiman		
RADEMARI	/	SHEET 2 OF 3	Attorney Docket No.	GNE.3230R1C61		
ADEMARIT						
MU	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	l Hans (basic massacine iscurse) social summasicum astolog eta \ data maga(a) colcuma isocia l			Т	
	21	GYGI, et al. Mar. 1999. Correlation betw Molecular and Cellular Biology, 1720-173		A Abundance in Yeast.		
,	22	HANASH, S. 2003. Making sense of microarr Journal, 3:308-311.	ay data to classify cance	er. The Pharmacogenomics		
	23	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.				
	24	HANCOCK, W. S. 2004. Do We Have Enoug	h Biomarkers? Journal o	of Proteome Research, 3(4):685.		
	25	HANNA, et al. Aug. 1999. HER-2/neu bre Medical Laboratories.	east cancer predictive t	testing. Pathology Associates		
	26	HAYNES, et al., 1998. Proteome analysi <i>Vol. 19</i> , pp. 1862- 1871.	s: Biological assay or	data archive? Electrophoresis,		
	27	HU, et al. 2003. Analysis of Genomic an Journal of Proteome Research, Vol. 2, pp.		ng Advanced Literature Mining.		
	28	HYMAN et al. Nov. 2002. Impact of DNA Cancer Research, 62:6240-6245.	•			
	29	JANG A. Hill RP, Sept. 1997. An examin starvation on the expression of metastas <i>Metastasis</i> 15(5): pp. 469-483				
	30	KONOPKA, et al. June 1986. Variable E Philadelphia-Chromosome-Positive B-Ly Leukemia Patients, <i>National Academy of</i> <i>No. 11</i> , pp. 4049-4052	mphoid Cell Lines fron	n Chronic Myelogenous		
	31	LEWIN, B. 1994. Oncogenes: Gene Exp Genes V. New York: Oxford University F		Chap. 39, pp.1196-1201.		
	32	LEWIN, B. 1997. Regulation of Transcrip Oxford University Press.				
	33	MEEKER, et al. 1990. Activation of the in acute lymphocytic leukemia with eosinop				
	34	MERIC, et al. 2002. Translation initiation Cancer Therapeutics, 1:971-979.				
	35	OHARA, et al. 2001. Directional cDNA libracombination reaction. <i>Nucleic Acids R</i>	esearch, Vol. 29, No e	22, pp.1-8.	_	
	36	ØRNTOFT, et al. 2002. Genome-wide st levels in pairs of non-invasive and invasive <i>Cellular Proteomics</i> , 1:37-45.	ve human transitional of	cell carcinomas. Molecular &		
	37	POLLACK, et al. 2002. Microarray analysalteration in the transcriptional program of				

Examiner Signature	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

	Application No.	10/063,587
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
ESTATEMENT BY APPLICANT	First Named Inventor	Goddard, et al.
STATEMENT BY APPLICANT	Art Unit	1646
ng of dultiple sheets used when necessary)	Examiner	Claire M. Kaufman
SHEET 3 OF 3	Attorney Docket No.	GNE.3230R1C61

TRADEMARK	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹			
	38	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics, Vol.5:</i> pp. 411-421.				
	39	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.				
	40	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.				
	41	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.				
	42	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.				

1780364/jk 062105

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.